Traferox Lands FDA Clearance for X°Port Heart System

Traferox Technologies has won FDA 510(k) clearance for X°Port, a static preservation system that holds a donor heart at 10°C during transport ahead of transplant — warmer than the roughly 4°C of conventional ice storage, a difference peer-reviewed studies tie to less primary graft dysfunction after transplant. Announced 22 September 2026, it is the Mississauga, Ontario company’s second FDA clearance in three months, after its TorEx Lung Perfusion System won premarket approval in July.

X°Port in four figures

10°Cthe static preservation temperature X°Port holds, versus roughly 4°C for conventional ice storage

4 hrsmaximum labeled preservation window under the FDA clearance

2FDA clearances or approvals Traferox has won since July 2026

$684MFortune Business Insights’ 2034 forecast for the global organ preservation market, up from $368.7M in 2026

Figures from the 22 September 2026 announcement and cited clinical literature.

Six degrees warmer than the cooler

For decades, the default way to move a donor heart from an operating room to a transplant center has been the simplest one: pack it in a sterile bag inside a cooler of ice, holding it near 4°C. Traferox’s X°Port keeps the organ warmer instead — a controlled 4 to 10°C, using a del Nido (or equivalent) cardioplegic solution, for up to four hours, which is the exact window and temperature range FDA cleared. The company points to published multicenter data, including work involving Vanderbilt and Duke transplant programs, showing hearts held at 10°C had better early graft function than those held at the conventional 4–8°C, with a smaller rise in blood lactate during extended ischemic time and higher cardiac index scores at 24 and 72 hours after transplant — despite similar use of drugs to support heart function.

“The FDA clearance of X°Port Heart marks an important milestone for Traferox and for the continued advancement of 10°C organ preservation. The strong clinical evidence supporting 10°C heart preservation, together with the successful adoption of 10°C preservation across leading lung transplant programs, has demonstrated the potential of this approach to improve donor organ preservation and transport.” Rick Mangat, Chief Executive Officer, Traferox Technologies — 22 September 2026 announcement

Static cold, not a pump

X°Port is a static device: the heart sits still at a controlled cold temperature rather than moving through continuous perfusion. That puts it in a different category from the machine-perfusion systems that have drawn most of the attention in organ transport, and Mangat’s reference to 10°C preservation’s “adoption across leading lung transplant programs” is a pointed one: Traferox’s founders, Dr. Shaf Keshavjee and Dr. Marcelo Cypel, built their reputations on ex vivo lung perfusion research at Toronto General Hospital, and the company is applying the same 10°C logic it used on lungs to hearts.

What X°Port is betting on

01

Static cold, not a pump

No perfusion pump, no circuit to prime and monitor in transit — X°Port competes on simplicity and cost against continuous machine perfusion for the standard-risk donor hearts that make up most transplants.

02

Built on published outcomes data

The 10–versus–4-to-8°C comparison behind the clearance is peer-reviewed multicenter work, not a company-run trial alone — the kind of independent evidence base a new preservation device rarely has this early.

03

A second FDA nod in three months

X°Port follows July’s FDA premarket approval of Traferox’s TorEx Lung Perfusion System, giving one Toronto-born transplant program two FDA-authorized organ-preservation products inside a single quarter.

A market two Boston rivals built

Donor-organ preservation has become a genuine device category rather than an afterthought, driven largely by two Massachusetts companies: Paragonix Technologies, whose SherpaPak Cardiac Transport System is a static, temperature-controlled canister already in wide transplant-center use, and TransMedics, whose OCS Heart keeps a donor heart warm, beating and perfused outside the body for transport windows well beyond what static cold storage is meant for. X°Port enters as a third static option, competing most directly with SherpaPak on the cases — the large majority of transplants — where a four-hour static window is enough and a running perfusion circuit is not needed.

Organ preservation’s slow, steady climb

$368.7M → $684.1M

Global organ preservation market, 2026 to 2034, as forecast by Fortune Business Insights (8.03% CAGR); heart transplantation itself is a separate, far larger market, which Coherent Market Insights forecasts at $14.12 billion in 2026 alone.

2025$323.8M

2026$368.7M

2034$684.1M

Sources: Fortune Business Insights, Organ Preservation Market · Coherent Market Insights, Heart Transplant Market

Regulatory News outlook

We expect 10°C static preservation, backed by peer-reviewed graft-dysfunction data most machine-perfusion systems can’t yet match on cost, to keep taking transplant centers from conventional ice storage faster than the organ-preservation market’s own published growth rate.

How we got here: Fortune Business Insights’ $368.7 million 2026 base, compounded at its own published 8.03% CAGR, reaches $684 million by 2034 ($368.7M × 1.0803^8 ≈ $684M) — that published line is our floor, not our estimate; any preservation method with outcomes data as strong as the one cited here would be expected to grow faster than that market-wide average, which is why we call it a floor rather than a forecast of our own.

Four ways to keep a donor heart cold

Product	Approach	Labeled duration	Regulatory status
X°Port (Traferox)	Static hypothermic, 4–10°C with del Nido (or equivalent) solution	Up to 4 hours	FDA 510(k), September 2026
SherpaPak Cardiac Transport System (Paragonix)	Static hypothermic, temperature-controlled canister	Labeled up to 4 hours; company-reported preclinical work to 30 hours	FDA-cleared, in commercial use
OCS Heart (TransMedics)	Continuous normothermic machine perfusion	Company has reported keeping a heart viable outside the body more than 15 hours	FDA-approved; an IDE trial for expanded claims is under way
Conventional ice storage	Static cold storage near 4°C, no dedicated device	Practice varies; commonly under 4 hours	Not a regulated device in the traditional sense

From each company’s own labelling, FDA records and public announcements; not a head-to-head clinical comparison.

From a Toronto transplant program to a second clearance

Two clearances, two months apart

1. 2021

   Traferox founded

   Spun out of University Health Network’s Toronto General Hospital transplant program by Dr. Shaf Keshavjee and Dr. Marcelo Cypel, to commercialize organ preservation research developed at UHN and the University of Toronto.

2. 22 July 2026

   TorEx Lung Perfusion System approved

   FDA premarket approval for Traferox’s ex vivo lung perfusion system, the company’s first major U.S. regulatory win.

3. 22 September 2026

   X°Port Heart Preservation System cleared

   FDA 510(k) clearance for static 4–10°C donor-heart preservation, exactly two months after the TorEx approval.

4. Ahead

   Commercial rollout

   The company has not published a U.S. launch timeline or pricing for X°Port.

What a four-hour window still limits

• Commercial rollout: no published U.S. launch date, pricing or initial transplant-center customers.
• Range: the four-hour static window keeps X°Port out of the longer-distance transports TransMedics’ machine perfusion is built for; Traferox is not claiming to replace that use case.
• Independent replication: the graft-dysfunction advantage cited for 10°C preservation comes from published multicenter studies rather than a Traferox-run trial; real-world adoption data specific to X°Port itself does not yet exist.

What is not yet public: the device’s 510(k) number in FDA’s own database, which the agency typically indexes within days of a clearance, and any transplant centers that have adopted X°Port since the announcement. We will update this page when FDA’s record and the company’s rollout details are published.

Frequently asked questions

What does the X°Port Heart Preservation System do?

It holds a donor heart in static hypothermic storage at 4 to 10°C for up to four hours during transport before transplant, using a del Nido (or equivalent) cold cardioplegic solution — warmer than the roughly 4°C of conventional ice storage, a difference peer-reviewed studies link to less graft dysfunction after transplant.

When did FDA clear it, and under what pathway?

FDA granted 510(k) clearance on 22 September 2026. It is Traferox’s second FDA clearance in three months, after the TorEx Lung Perfusion System won FDA premarket approval on 22 July 2026.

How is X°Port different from TransMedics’ OCS Heart?

X°Port is a static system: the heart sits at a controlled cold temperature, not moving through a pump. TransMedics’ OCS Heart is a machine-perfusion system that keeps a heart warm and beating outside the body, a different approach aimed at longer transport times and marginal donor organs.

Who is Traferox Technologies?

A Mississauga, Ontario medical device company founded in 2021 as a spin-out of the University Health Network’s Toronto General Hospital transplant program, co-founded by transplant surgeons Dr. Shaf Keshavjee and Dr. Marcelo Cypel.